Cu(II)ATSM is under clinical development by Collaborative Medicinal Development and currently in Phase III for Amyotrophic Lateral Sclerosis. According to GlobalData, Phase III drugs for Amyotrophic Lateral Sclerosis have a 32% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Cu(II)ATSM’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Cu(II)ATSM overview
Cu(II)ATSM is under development for the treatment of Parkinson's disease and amyotrophic lateral sclerosis. It is administered orally. The drug candidate is bis (thiosemicarbazone) derivative. It targets superoxide dismutase (SOD1). It is a copper-containing synthetic small molecule.
Collaborative Medicinal Development overview
Collaborative Medicinal Development (CMD) is a biopharmaceutical company that develops novel therapeutics to treat neurodegenerative diseases and cancer. The company’s pipeline products include CuATSM a small synthetic molecule that contains copper that eliminates peroxynitrite which is a chemical that inhibits components of the mitochondrial electron transport chain in amyotrophic lateral sclerosis (ALS). It also develops small-molecule ferroptosis inhibitors as first-in-class treatments for neurodegenerative diseases. CMD is advancing its therapeutics to treat Alzheimer’s disease, Huntington’s disease, and Parkinson’s disease. The company has operations in the US and Australia.CMD is headquartered in Mill Valley, California, the US.
For a complete picture of Cu(II)ATSM’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
